Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (NP101-008)

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( NuPathe Inc. ) Identifier:
First received: November 14, 2008
Last updated: February 2, 2016
Last verified: February 2016

The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by:

  • Subject self-examination skin irritation scores
  • Adverse events
  • Changes in vital signs and ECG parameters

The secondary objective is to evaluate the long term efficacy of NP101 as assessed by:

  • Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101
  • Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101

This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch).

Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.

Condition Intervention Phase
Migraine Disorders
Drug: NP101
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Subject Self-examination of Skin Irritation [ Time Frame: 24 hours post patch activation ]
    For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin).

Secondary Outcome Measures:
  • Pain Relief [ Time Frame: 2 hours ]
    Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101.

  • Nausea Free [ Time Frame: 2 hours ]
    Nausea free at two hours after patch activation.

  • Phonophobia Free [ Time Frame: 2 hours ]
    Phonophobia free at two hours after patch activation.

  • Photophobia Free [ Time Frame: 2 hours ]
    Photophobia free at two hours after patch activation.

Enrollment: 198
Study Start Date: January 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NP101
sumatriptan iontophoretic transdermal patch
Drug: NP101
NP101 study patch 4 hour application


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject was previously enrolled in study NP101-007 and treated (patch activation) a qualifying migraine.
  • Subject will be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, and ECG. Subjects will not have any clinically significant abnormal vital signs or ECG parameters in order to qualify for enrollment. ECG must be done at enrollment for NP101-008 unless ECG for the Final Visit of study NP101-007 was conducted within 30 days.
  • Female subjects of childbearing potential (not surgically sterile or 2 years post menopausal) must have a negative pregnancy test at enrollment.

Exclusion Criteria:

  • Subject has less than two potential skin application sites.
  • Subject has clinically significant abnormal vital signs or ECG parameters or had an adverse event while participating in NP101-007 that would preclude the continued treatment with the NP101 patch.
  • Subject has had changes in their medical history or medication use that would preclude their use of sumatriptan as per the approved Imitrex® product Prescribing Information (PI) or their safe use of NP101 as per the NP101 Investigator's Brochure.
  • Subject has or plans to start, stop, change treatment or dose of any of the following within 3 months prior to the subject's study Enrollment date and through the Final Visit: anxiolytics, lithium and other mood stabilizers such as valproate, carbamazepine or lamotrigine, hypnotics or antipsychotics.
  • Subject has taken non-triptan serotonergic drugs including selective serotonin reuptake inhibitor (SSRI), serotonin and norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCAs), monoamine oxidase inhibitor (MAOI) or preparations containing St. John's Wort within 1 month prior to enrollment and/or is planning to start any of these medications during the study (through Final Visit).
  • Female subjects who are pregnant, breast feeding, or of childbearing potential, and are not using or are unwilling to use an effective form of contraception during the study and for a period of 30 days following Final Visit. Acceptable methods of contraception include barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted or injected) or abstinence. If the exclusive male partner is surgically sterile, this will be acceptable.
  • Subject has participated in a clinical study within 30 days of enrollment (excluding NP101-007) or is planning to participate in another clinical study for the duration of NP101-008.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00792103

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Newport Beach, California, United States
San Francisco, California, United States
Santa Monica, California, United States
United States, Connecticut
Fairfield, Connecticut, United States
United States, Florida
Ocala, Florida, United States
Palm Beach Gardens, Florida, United States
Sunrise, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Columbus, Georgia, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Michigan
Ann Arbor, Michigan, United States
Kalamazoo, Michigan, United States
United States, Missouri
Springfield, Missouri, United States
St. Louis, Missouri, United States
United States, New York
Mount Vernon, New York, United States
Plainview, New York, United States
United States, North Carolina
Greensboro, North Carolina, United States
United States, Ohio
West Chester, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Alexandria, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Seattle, Washington, United States
Sponsors and Collaborators
NuPathe Inc.
Study Chair: Mark Pierce, MD PhD NuPathe Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: NuPathe Inc. Identifier: NCT00792103     History of Changes
Other Study ID Numbers: PROT-15-NP101-008
Study First Received: November 14, 2008
Results First Received: February 15, 2013
Last Updated: February 2, 2016

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on April 28, 2017